Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to hereditary neuronal sodium ion channel mutations Adolore's Kv7 voltage-gated ...

Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.

This exploratory study in healthy young adults found that plasma sodium levels within the normal clinical range are ...

Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...